Vol 6, Supplement 1 (December 2017): Translational Lung Cancer Research

Original Article

Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC)
Rezarta Frakulli, Fabrizio Salvi, Damiano Balestrini, Marcella Palombarini, Ilir Akshija, Silvia Cammelli, Alessio Giuseppe Morganti, Maurizio Zompatori, Giovanni Frezza
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta- analysis
Yang-Bo Hu, Qun Zhang, Hui-Juan Li, Jean Maire Michot, Hong-Bing Liu, Ping Zhan, Tang-Feng Lv, Yong Song, written on behalf of the AME Academic Lung Cancer Cooperation Group


Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer
Ignacio Gil-Bazo
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study
Aaron Lisberg, Edward B. Garon
Avelumab: another active immune checkpoint inhibitor in nonsmall cell lung cancer
Hao Xie, Alex A. Adjei
Young low and middle-income country (LMIC) smokers— implications for global tobacco control
Emily Stone, Matthew Peters
Perspectives in small cell lung cancer: is something moving?
Lucio Crinò, Angelo Delmonte
Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them
Marius Ilie, Paul Hofman
The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated nonsmall cell lung cancer
Anthony M. Brade
Raising the bar: the future of EGFR inhibition in non-small lung cancer
Amanda J. Redig
Osimertinib as first-line treatment of EGFR mutant advanced nonsmall- cell lung cancer
Chong-Kin Liam
Small-cell lung cancer in the era of immunotherapy
Margarita Majem, Charles M. Rudin
Can we omit radiotherapy in case of brain metastases for patients with mutant EGFR lung adenocarcinoma?
Paul Jules Van Houtte, Daniel Devriendt
The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?
Giancarlo Troncone, Cesare Gridelli
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
Alejandro Navarro, Enriqueta Felip
KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?
Jose M. Pacheco, D. Ross Camidge
Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?
Wolfram C. M. Dempke, Klaus Fenchel